# EnChannel Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enchannel-medical

- Industry: Healthcare Specialists
- Headquarters: Guangzhou, China
- Website: www.enchannel.com
- Total disclosed funding: $110M
- Latest round: Series B (May 1, 2025)
- Investors on record: 3

## About

Established in 2020 and based in Guangzhou, China, EnChannel operates as a medical technology company that provides atrial fibrillation treatment solutions and related products. The company is headquartered in Guangzhou and has offices in United States and Shanghai. Jun Feng, the co-founder and CEO of the company, has 28 years of experience in the clinical and medical technology fields of medicine and worked at Medtronic and St. Jude, Inc. Min Zhu, the co-founder and CTO of the company, once served as the chief applied mathematician, director of Engineering of Algorithms at Acutus Medical. In August 2023, it raised CNY 200 million in series A funding co-led by Lapam Capital and Lilly Asia Ventures. 

The company engages in the research and development of atrial fibrillation therapy products using 3D labeling and PFA ablation technologies. Its products include NanoAblate™ pulsed field ablator, PFLine linear pulsed electric field ablation catheter, PFBasket shaped pulsed field ablation catheter and DePolar 4D cardiac labeling system, etc. Products can treat patients with paroxysmal atrial fibrillation and atrial flutter.

## Funding rounds

- Series B, May 1, 2025, $82M — Lilly Asia Ventures, Lapam Capital, Long Z Investment
- Series A, Aug 1, 2023, $28M — Lilly Asia Ventures, Lapam Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A, Series B
- Long Z Investment (https://capitalatlas.ai/funds/long-z-investment) — Series B